Astra Wealth Partners LLC Makes New $246,000 Investment in AtriCure, Inc. (NASDAQ:ATRC)

Astra Wealth Partners LLC purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 8,048 shares of the medical device company's stock, valued at approximately $246,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of AtriCure during the fourth quarter worth $3,716,000. Norges Bank bought a new stake in shares of AtriCure in the 4th quarter valued at about $3,421,000. JPMorgan Chase & Co. raised its position in shares of AtriCure by 43.1% in the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock valued at $11,160,000 after acquiring an additional 110,039 shares during the period. Two Sigma Advisers LP boosted its stake in AtriCure by 14.6% during the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company's stock worth $18,621,000 after acquiring an additional 84,700 shares during the last quarter. Finally, State Street Corp increased its stake in AtriCure by 4.9% in the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after purchasing an additional 63,002 shares in the last quarter. 99.11% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Oppenheimer boosted their price target on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Stifel Nicolaus increased their price target on AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. JMP Securities reaffirmed a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a research report on Monday, February 10th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. Finally, JPMorgan Chase & Co. dropped their target price on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $49.44.

Remove Ads

AtriCure Stock Up 0.5 %

AtriCure stock traded up $0.14 during mid-day trading on Wednesday, reaching $30.75. The company's stock had a trading volume of 135,234 shares, compared to its average volume of 597,928. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11. The business's 50 day simple moving average is $36.63 and its 200 day simple moving average is $34.21. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -32.37 and a beta of 1.65.

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.20% of the stock is owned by corporate insiders.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.